A $340 million exit on a Series C investment made less than two years ago is the headline number, but the more instructive figure sits one layer down: Angelini Ventures joined Noctrix Health’s financing round in 2024 at a $40 million raise, making this its first realized exit since the fund launched in 2022 with a €300 million commitment. The return multiple isn’t disclosed, but the velocity — from Series C participation to acquisition close in under 24 months — signals something deliberate about how the firm was positioning Noctrix for a strategic buyer rather than a standalone commercial buildout.
The asset ResMed just absorbed isn’t a speculative platform play. Nidra, Noctrix’s wearable tonic motor activation device, received FDA De Novo authorization in April 2023 for medication-refractory, moderate-to-severe primary RLS, following a Breakthrough Device Designation and a multicenter randomized sham-controlled trial. That regulatory pathway matters for deal logic: De Novo classification establishes a new predicate, which means the product controls the device category it defines. ResMed isn’t buying a pipeline candidate — it’s acquiring a cleared, commercially active device with a defensible regulatory moat, designed to slot into the connected sleep health infrastructure ResMed already operates at scale. The deal closed June 1, 2026.
The underlying market logic is durable. Global RLS prevalence among adults aged 20–79 was estimated at roughly 356 million individuals as of 2019, with moderate-to-severe cases — the exact population Nidra targets — representing a substantial subset chronically underserved by existing pharmacological options. RLS has long been managed with dopaminergic agents and alpha-2-delta ligands that carry tolerability and augmentation problems at higher doses. A non-invasive, wearable neuromodulation alternative that sidesteps those pharmacological liabilities fits cleanly into ResMed’s pitch to payers and health systems about comprehensive, tech-enabled sleep care. This isn’t a bolt-on novelty; it extends ResMed’s addressable clinical surface from respiratory-driven sleep disruption into neurological sleep pathology.
For Angelini Ventures, the exit resets the narrative around European corporate venture arms: the fund now has proof of concept on its core thesis before most of its 25-company portfolio has reached maturity. The metric worth tracking is whether the EIB’s €150 million co-financing partnership announced in December 2025 accelerates follow-on rounds for other portfolio companies toward similarly fast acquisition timelines — or whether Noctrix was a structural outlier that benefited from uniquely clean regulatory timing.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
